|
1
|
Ries LAG, Eisner MP, Kosary CL, et al:
SEER Cancer Statistics Review 1973–1998. National Cancer Institute;
Bethesda, MD: 2001
|
|
2
|
National Institutes of Health.
Surveillance epidemiology and end results. Available at: http://seer.cancer.gov/.
2008
|
|
3
|
Adjei AA: A review of the pharmacology and
clinical activity of new chemotherapy agents for the treatment of
colorectal cancer. J Clin Pharmacol. 48:265–277. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lichtman SM and Villani G: Chemotherapy in
the elderly: pharmacologic considerations. Cancer Control.
7:548–556. 2000.PubMed/NCBI
|
|
5
|
Folprecht G, Seymour MT, Saltz L, et al:
Irinotecan/fluorouracil combination in first-line therapy of older
and younger patients with metastatic colorectal cancer: combined
analysis of 2,691 patients in randomized controlled trials. J Clin
Oncol. 26:1443–1451. 2008. View Article : Google Scholar
|
|
6
|
Feliu J, Escudero P, Llosa F, et al:
Capecitabine as first-line treatment for patients older than 70
years with metastatic colorectal cancer: an Oncopaz Cooperative
Group study. J Clin Oncol. 23:3104–3111. 2005.PubMed/NCBI
|
|
7
|
Cassidy J, Twelves C, Van Cutsem E, et al:
First-line oral capecitabine therapy in metastatic colorectal
cancer: a favorable safety profile compared with intravenous
5-fluorouracil/leucovorin. Ann Oncol. 13:566–575. 2002. View Article : Google Scholar
|
|
8
|
Ho C, Ng K, O’Reilly S and Gill S:
Outcomes in elderly patients with advanced colorectal cancer
treated with capecitabine: a population-based analysis. Clin
Colorectal Cancer. 5:279–282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jensen SA, Lonborg JT and Sorensen JB:
Benefits and risk of palliative capecitabine-based therapy to
elderly patients with advanced colorectal cancer: Danish single
center experiences. Acta Oncol. 45:67–76. 2006. View Article : Google Scholar
|
|
10
|
Stec R, Bodnar L and Szczylik C:
Feasibility and efficacy of capecitabine and FOLFIRI in patients
aged 65 years and older with advanced colorectal cancer: a
retrospective analysis. J Cancer Res Clin Oncol. 136:283–292.
2010.PubMed/NCBI
|
|
11
|
Arkenau HT, Graeven U, Kubicka S, et al:
Oxaliplatin in combination with 5-fluorouracil/leucovorin or
capecitabine in elderly patients with metastatic colorectal cancer.
Clin Colorectal Cancer. 7:60–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Twelves CJ, Butts CA, Cassidy J, et al:
Capecitabine/oxaliplatin, oxaliplatin a safe and active first-line
regiment for older patients with metastatic colorectal cancer: post
hoc analysis of a large phase II Study. Clin Colorectal Cancer.
5:101–107. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feliu J, Salud A, Escudero P, et al: XELOX
(capecitabine plus oxaliplatin) as first-line treatment for
patients over 70 years of age with advanced colorectal cancer. Br J
Cancer. 94:969–975. 2006.PubMed/NCBI
|
|
14
|
Tabah-Fisch I, Maindrault-Goebel F,
Benavides M, et al: Oxaliplatin/5 FU/LV is feasible, safe and
active in elderly colorectal cancer (CRC) patients. ASCO abs.
556:2002.
|
|
15
|
Goldberg RM, Tabah-Fisch I, Bleiberg H, et
al: Pooled analysis of safety and efficacy of oxaliplatin plus
fluorouracil/lecovorin administered bimonthly in elderly patients
with colorectal cancer. J Clin Oncol. 24:4085–4091. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bruce C, Köhne C-H and Audisio RA:
Treatment of advancedcolorectal cancer in the elderly. Eur J Surg
Oncol. 84–87. 2007. View Article : Google Scholar
|
|
17
|
Jackson NA, Barrueco J, Soufi-Mahjoubi R,
et al: Comparing safety and efficacy of first-line
irinitecan/fluorropyrimidine combinations in eldery versus
nonelderly patients with metastatic colorectal cancer. Cancer.
115:2617–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gràvalos C, River F, Massuti B, et al:
Cetuximab and capecitabine as first-line treatment for elderly
patient (pts) with metastatic colorectal cancer (mCRC): preliminary
results of TTD trial. (suppl). J Clin Oncol. 26:2008.
|
|
19
|
Sastre J, Aranda E, Gràvalos C, et al:
First-line single-agent cetuximab in elderly patients with
metastatic colorectal cancer. A phase II clinical and molecular
study of the Spanish group for digestive tumor therapy (TTD). Crit
Rev Oncol Hematol. Dec. 28;2009.(Epub ahead of print).
|
|
20
|
Hecht JR, Mitchell E, Chidiac T, et al: A
randomized phase IIIB trial of chemotherapy, bevacizumab, and
panitumumab compared with chemotherapy and bevacizumab alone for
metastatic colorectal cancer. J Clin Oncol. 27:672–680. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectalcancer. Gastroenterology. 134:1296–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saltz L, Clarke S, Diaz-Rubio E, et al:
Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated
efficacy results from XELOX-1/NO16966, a randomized phase III trial
in first line metastatic colorectal cancer. J Clin Oncol.
25:18S2007.
|
|
23
|
Sama A, Gonsalves W, Aldoss I, et al:
Adjuvant chemotherapy for colon cancer patients age 80 and older:
Veteran’s Affairs Central Cancer (VACCR) database analysis.
Gastrointestinal Cancers Symposium ASCO abs. 450:2010.
|
|
24
|
Köhne C-H, Folprecht G, Goldberg RM, et
al: Chemotherapy in elderly patients with colorectal cancer.
Oncologist. 13:390–402. 2008.
|
|
25
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
